{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:20:41Z","timestamp":1791109241887,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s10067-008-0866-4","type":"journal-article","created":{"date-parts":[[2008,3,18]],"date-time":"2008-03-18T18:11:20Z","timestamp":1205863880000},"page":"1021-1028","source":"Crossref","is-referenced-by-count":69,"title":["An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status"],"prefix":"10.1007","volume":"27","author":[{"given":"Arie E.","family":"van der Bijl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand C.","family":"Breedveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian E.","family":"Antoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim R.","family":"Kalden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Kary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R.","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Unnebrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Kupper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,3,19]]},"reference":[{"key":"866_CR1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26\u201337","journal-title":"Arthritis Rheum"},{"key":"866_CR2","first-page":"1232","volume":"32","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Bathon JM, Fleischmann RM et al (2005) Long-term safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 32:1232\u20131242","journal-title":"J Rheumatol"},{"key":"866_CR3","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"EC Keystone","year":"2004","unstructured":"Keystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400\u20131411","journal-title":"Arthritis Rheum"},{"key":"866_CR4","first-page":"CD005113","volume":"3","author":"F Navarro-Sarabia","year":"2005","unstructured":"Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B et al (2005) Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev 3:CD005113","journal-title":"Cochrane Database Syst Rev"},{"key":"866_CR5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","volume":"54","author":"JS Smolen","year":"2006","unstructured":"Smolen JS, van der Heijde DM, St Clair EW et al (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54:702\u2013710","journal-title":"Arthritis Rheum"},{"key":"866_CR6","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","volume":"50","author":"EW St. Clair","year":"2004","unstructured":"St. Clair EW, van der Heijde DM, Smolen JS et al (2004) Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset study group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432\u20133443","journal-title":"Arthritis Rheum"},{"key":"866_CR7","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/art.21655","volume":"54","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Klareskog L, Rodriguez-Valverde V et al (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54:1063\u20131074","journal-title":"Arthritis Rheum"},{"key":"866_CR8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003495-200565050-00006","volume":"65","author":"MT Nurmohamed","year":"2005","unstructured":"Nurmohamed MT, Dijkmans BA (2005) Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 65:661\u2013694","journal-title":"Drugs"},{"key":"866_CR9","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/art.22520","volume":"56","author":"A Finckh","year":"2007","unstructured":"Finckh A, Ciurea A, Brulhart L et al (2007) B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 56:1417\u20131523","journal-title":"Arthritis Rheum"},{"key":"866_CR10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jbspin.2004.07.009","volume":"71","author":"O Brocq","year":"2004","unstructured":"Brocq O, Albert C, Roux C et al (2004) Adalimumab in rheumatoid arthritis after failed infliximab and\/or etanercept therapy: experience with 18 patients. Joint Bone Spine 71:601\u2013603","journal-title":"Joint Bone Spine"},{"key":"866_CR11","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","volume":"8","author":"JJ Gomez-Reino","year":"2006","unstructured":"Gomez-Reino JJ, Carmona L, for the BIOBADASER Group (2006) Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8:R29","journal-title":"Arthritis Res Ther"},{"key":"866_CR12","first-page":"1098","volume":"31","author":"KE Hansen","year":"2004","unstructured":"Hansen KE, Hildebrand JP, Genovese MC et al (2004) The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 31:1098\u20131102","journal-title":"J Rheumatol"},{"key":"866_CR13","first-page":"2356","volume":"31","author":"B Haraoui","year":"2004","unstructured":"Haraoui B, Keystone EC, Thorne JC et al (2004) Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 31:2356\u20132359","journal-title":"J Rheumatol"},{"key":"866_CR14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/ard.2005.039099","volume":"65","author":"SN Nikas","year":"2006","unstructured":"Nikas SN, Voulgari PV, Alamanos Y et al (2006) Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 65:257\u2013260","journal-title":"Ann Rheum Dis"},{"key":"866_CR15","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/ard.2003.009589","volume":"62","author":"R Vollenhoven van","year":"2003","unstructured":"van Vollenhoven R, Harju A, Brannemark S et al (2003) Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor \u03b1 blockers can make sense. Ann Rheum Dis 62:1195\u20131198","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 35","key":"866_CR16","first-page":"S115","volume":"22","author":"RF Vollenhoven Van","year":"2004","unstructured":"Van Vollenhoven RF (2004) Switching between biologic agents. Clin Exp Rheumatol 22(Suppl 35):S115\u2013S121","journal-title":"Clin Exp Rheumatol"},{"key":"866_CR17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","volume":"56","author":"KL Hyrich","year":"2007","unstructured":"Hyrich KL, Lunt M, Watson K et al (2007) Outcomes after switching from one anti-tumor necrosis factor \u03b1 agent to a second anti-tumor necrosis factor \u03b1 agent in patients with rheumatoid arthritis. Arthritis Rheum 56:13\u201320","journal-title":"Arthritis Rheum"},{"key":"866_CR18","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/rheumatology\/kem091","volume":"46","author":"S Bombardieri","year":"2007","unstructured":"Bombardieri S, Ruiz AA, Fardellone P, for the Research in Active Rheumatoid Arthritis (ReAct) Study Group et al (2007) Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 46:1191\u20131199","journal-title":"Rheumatology (Oxford)"},{"key":"866_CR19","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/ard.2006.054742","volume":"66","author":"E Hjardem","year":"2007","unstructured":"Hjardem E, Ostergaard M, P\u00f8denphant J et al (2007) Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis 66:1184\u20131189","journal-title":"Ann Rheum Dis"},{"key":"866_CR20","first-page":"795","volume":"23","author":"G Cohen","year":"2005","unstructured":"Cohen G, Courvoisier N, Cohen JD et al (2005) The efficacy of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 23:795\u2013800","journal-title":"Clin Exp Rheumatol"},{"key":"866_CR21","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0003-4967(24)18551-2","volume":"63","author":"JA Gomez-Puerta","year":"2004","unstructured":"Gomez-Puerta JA, Sanmarti R, Rodriguez-Cros JR et al (2004) Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy. Ann Rheum Dis 63:896","journal-title":"Ann Rheum Dis"},{"key":"866_CR22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/03009740510026887","volume":"34","author":"MC Wick","year":"2005","unstructured":"Wick MC, Ernestam S, Lindblad S et al (2005) Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 34:353\u2013358","journal-title":"Scand J Rheumatol"},{"key":"866_CR23","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/rheumatology\/keh673","volume":"44","author":"AN Bennett","year":"2005","unstructured":"Bennett AN, Peterson P, Zain A et al (2005) Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology (Oxford) 44:1026\u20131031","journal-title":"Rheumatology (Oxford)"},{"key":"866_CR24","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","volume":"54","author":"GJ Wolbrink","year":"2006","unstructured":"Wolbrink GJ, Vis M, Lems WF et al (2006) Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54:711\u2013715","journal-title":"Arthritis Rheum"},{"key":"866_CR25","unstructured":"Humira\u00ae [package insert] (2006) Chicago, IL: Abbott Laboratories"},{"issue":"Suppl","key":"866_CR26","first-page":"S140","volume":"48","author":"WM Awni","year":"2003","unstructured":"Awni WM, Cascella P, Oleka N et al (2003) Steady-state pharmacokinetics of adalimumab (Humira) following 40 mg subcutaneous injection every other week in rheumatoid arthritis patients with and without methotrexate background therapy [poster 255]. Arthritis Rheum 48(Suppl):S140","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"866_CR27","first-page":"S140","volume":"48","author":"RG Granneman","year":"2003","unstructured":"Granneman RG, Zhang Y, Noertersheuser PA et al (2003) Pharmacokinetic\/pharmacodynamic relationships of adalimumab (Humira) in rheumatoid arthritis patients during phase II\/III clinical trials [poster 256]. Arthritis Rheum 48(Suppl):S140","journal-title":"Arthritis Rheum"},{"key":"866_CR28","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT et al (2007) Clinical response to adalimumab: Relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66:921\u2013926","journal-title":"Ann Rheum Dis"},{"key":"866_CR29","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","volume":"63","author":"LBA Putte van de","year":"2004","unstructured":"van de Putte LBA, Atkins C, Malaise M et al (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63:508\u2013516","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-008-0866-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T04:26:35Z","timestamp":1738124795000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-008-0866-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,19]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["866"],"URL":"https:\/\/doi.org\/10.1007\/s10067-008-0866-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,19]]}}}